LBA
Letko, Brosseau & Associates Portfolio holdings
AUM
$6.77B
Turnover
14.78%
1-Year Est. Return
38.11%
This Fund
S&P 500
This Quarter
Est. Return
+9.71%
1 Year Est. Return
+38.11%
3 Year Est. Return
+83.35%
5 Year Est. Return
+109.01%
10 Year Est. Return
+317.99%
AUM
$6.77B
AUM Growth
+$562M
(+9.1%)
Cap. Flow
+$52.1M
Cap. Flow
% of AUM
0.77%
Top 10 Holdings %
Top 10 Hldgs %
37.57%
Holding
115
New
14
Increased
26
Reduced
50
Closed
3
Avg Time Held
5.5
years
Top 10 Avg Time Held
6.5
years
Top 20 Avg Time Held
6.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE HealthCare
GEHC
|
+$57.7M |
| 2 |
Gildan
GIL
|
+$54.4M |
| 3 |
Exelon
EXC
|
+$41.2M |
| 4 |
Telus
TU
|
+$33.9M |
| 5 |
Comcast
CMCSA
|
+$30.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$186M |
| 2 |
Bank of Montreal
BMO
|
+$24.1M |
| 3 |
Suncor Energy
SU
|
+$16.5M |
| 4 |
Enerflex
EFXT
|
+$14.5M |
| 5 |
Magna International
MGA
|
+$13.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 32.78% |
| 2 | Communication Services | 16.83% |
| 3 | Healthcare | 10.42% |
| 4 | Technology | 9.49% |
| 5 | Materials | 8.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Apple
AAPL
$5.01T
| $217K | ﹤0.01% |
+750
| New | +$215K |
2026 Q2
0 quarters
|
|
102
Oracle
ORCL
$396B
| $208K | ﹤0.01% |
1,420
| – | – |
2025 Q2
4 quarters
|
|
103
Mastercard
MA
$528B
| $205K | ﹤0.01% |
+400
| New | +$199K |
2026 Q2
0 quarters
|
|
104
Denali Therapeutics
DNLI
$2.86B
| $202K | ﹤0.01% |
+7,850
| New | +$161K |
2026 Q2
0 quarters
|
|
105
Aura Biosciences
AURA
$640M
| $201K | ﹤0.01% |
28,300
| – | – |
2024 Q1
9 quarters
|
|
106
IAMGOLD
IAG
$9.74B
| $198K | ﹤0.01% |
+12,500
| New | +$218K |
2026 Q2
0 quarters
|
|
107
Tenax Therapeutics
TENX
$57.3M
| $155K | ﹤0.01% |
10,650
| – | – |
2025 Q4
2 quarters
|
|
108
Aquestive Therapeutics
AQST
$579M
| $147K | ﹤0.01% |
35,325
| – | – |
2025 Q4
2 quarters
|
|
109
TScan Therapeutics
TCRX
$14.3M
| $94K | ﹤0.01% |
95,875
| – | – |
2023 Q3
11 quarters
|
|
110
Aldeyra Therapeutics
ALDX
$47.7M
| $36.8K | ﹤0.01% |
17,300
| – | – |
2024 Q4
6 quarters
|
|
111
Humacyte
HUMA
$98.4M
| $35.9K | ﹤0.01% |
45,950
| – | – |
2025 Q1
5 quarters
|
|
112
ProKidney
PROK
$307M
| $32.4K | ﹤0.01% |
15,900
| – | – |
2025 Q3
3 quarters
|
|
113
Alphabet (Google) Class A
GOOGL
$4.25T
| – | – |
-1,092
| Closed | -$314K | – |
|
114
Gossamer Bio
GOSS
$54.4M
| – | – |
-493
| Closed | -$12.9K | – |
|
115
Replimune Group
REPL
$1.07B
| – | – |
-10,800
| Closed | -$82.6K | – |
|
Similar funds
JWBC
MCM
CAG
LSERS
CAI
TCM
LIP
RWM
Letko, Brosseau & Associates's Q2 2026 Portfolio in Review
As of Q2 2026, Letko, Brosseau & Associates held 115 positions worth $6.77B, up 9.1% from $6.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Letko, Brosseau & Associates's Q2 2026 filing shows 14 new, 26 increased, 50 reduced and 3 closed positions. Its largest new stake was GE HealthCare: 878,575 shares worth $56.2M. The largest sale was Intel, an estimated $186M.
By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 30% a quarter earlier, followed by Communication Services and Healthcare.
- Letko, Brosseau & Associates's largest Q2 2026 buy was GE HealthCare: 878,575 shares worth $56.2M.
- Letko, Brosseau & Associates added most to Telus in Q2 2026, an estimated $33.9M increase.
- Letko, Brosseau & Associates's biggest Q2 2026 reduction was Intel, cutting an estimated $186M.
- Letko, Brosseau & Associates fully exited Alphabet (Google) Class A in Q2 2026, selling an estimated $314K.
- Letko, Brosseau & Associates's ten largest holdings make up 38% of its $6.77B portfolio in Q2 2026.
- Letko, Brosseau & Associates opened 14 new positions and closed 3 in Q2 2026.
- Letko, Brosseau & Associates's portfolio value rose 9.1% quarter-over-quarter to $6.77B.
Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.